While aldosterone receptor blockers improve survival of patients with congestive heart failure, spironolactone and its derivatives were recently shown to block ether-a-go-gorelated gene (HERG) channels and native I Ks and I Kr currents in guinea pig ventricular myocytes. In this study, we examined in vivo electropharmacological effects of an active derivative of spironolactone, potassium canrenoate, using a halothane-anesthetized canine model. Potassium canrenoate was intravenously administered in three doses of 1, 10, and 100 mg / kg per 10 min with a pause of 20 min between doses (n = 5). The low dose hardly affected any of the cardiovascular parameters. The middle dose, a clinically recommended daily maximum i.v. dose, slightly inhibited the intraventricular conduction. The high dose decreased the heart rate, ventricular contraction and blood pressure, delayed the atrioventricular and intraventricular conduction, and prolonged the ventricular repolarization and refractory period. Increment in the refractoriness by the high dose was greater than that in the repolarization, resulting in the reduction of ventricular electrical vulnerability. This unique electrophysiological profile of potassium canrenoate may in part contribute to the favorable clinical results, whereas caution has to be paid on the cardiohemodynamic actions, particularly for patients with risk of elevated plasma drug concentration.
Introduction
The Randomized Aldactone Evaluation Study (RALES) showed that addition of spironolactone to a standard multidrug therapy substantially reduced the risk of both morbidity and mortality among patients with severe heart failure (1) . Based on this observation, spironolactone has been suggested to act on non-renal tissue; namely the heart, aorta together with its major branches, and autonomic nervous system, besides the natriuretic effect (1) . Also, antiarrhythmic potential of spironolactone and its derivatives has been indicated in basic experiments (2, 3) as well as in a clinical study (4) . However, these drugs were recently shown to block ether-a-go-go-related gene (HERG) channels and native rapid (I Kr ) and slow (I Ks ) components of the delayed rectifier K + currents in guinea pig ventricular myocytes (5) , indicating proarrhythmic potential via excessive QT interval prolongation (6 -9) .
Since the drug-induced long QT syndrome is a hot topic of concern for the pharmaceutical companies as well as clinicians, in this study we simultaneously assessed the cardiohemodynamic and electrophysiological effects of a spironolactone active derivative potassium canrenoate, using the halothane-anesthetized in vivo canine model (9 -15) . To better analyze the electrophysiological effects of the drug on the depolarization and repolarization phases, we recorded the His bundle electrograms and monophasic action potentials (MAPs), respectively, in addition to the standard lead II ECG. Moreover, a MAP recording / pacing combination catheter was used to simultaneously measure both MAP and effective refractory period (ERP) at the same site and directly compare the drug effects on the repolarization and refractoriness (9 -15) . Assessment of these actions would provide a better understanding of the efficacy and adversity of spironolactone in clinical practice (1) .
Materials and Methods
Experiments were carried out using five beagle dogs of either sex weighing approximately 10 kg. Animals were obtained through the Animal Laboratory for Research of University of Yamanashi. All experiments were performed according to Guidelines for Animal Experiments, University of Yamanashi.
Cardiohemodynamic parameters
Dogs were anesthetized initially with thiopental sodium (30 mg / kg, i.v.). After intubation with a cuffed endotracheal tube, 1% halothane vaporized with 100% oxygen was inhaled with a volume-limited ventilator (SN-480-3; Shinano, Tokyo). Tidal volume and respiratory rate were set at 20 ml / kg and 15 strokes / min, respectively. To prevent blood clotting, heparin calcium (100 IU / kg) was intravenously administered. A heparinized catheter was placed in the aorta for continuous monitoring of the systemic blood pressure through the right femoral artery. A thermodilution catheter (TC-704; Nihon Kohden, Tokyo) was positioned at the right side of the heart through the right femoral vein. The cardiac output (CO) was measured by a standard thermodilution method using a cardiac output computer (MFC-1100, Nihon Kohden). The total peripheral resistance (TPR) was calculated using the basic equation: TPR = mean blood pressure / cardiac output. A pig-tail catheter was positioned at the left ventricle through the right femoral artery to measure the left ventricular pressure. The maximum upstroke velocity of the left ventricular pressure (LVdP/ dt max ) and the left ventricular end-diastolic pressure (LVEDP) were obtained during sinus rhythm to estimate the contractility and the preload to the left ventricle, respectively.
Electrophysiological parameters
The surface lead II ECG was obtained from the limb electrodes. Corrected QT interval (QTc) was calculated using Bazett's and Van de Water's formulas (16, 17) . A quad-polar electrodes catheter was positioned at the non-coronary cusp of the aortic valve through the left femoral artery to obtain the His bundle electrogram. A bi-directional steerable monophasic action potential (MAP) recording / pacing combination catheter (1675P; EP Technologies, Inc., Sunnyvale, CA, USA) was posi-tioned at the endocardium of the right ventricle through the left femoral vein to obtain MAP signals. The signals were amplified with a DC preamplifier (model 300; EP Technologies, Inc.). The duration of the MAP signals was measured as an interval, along a line horizontal to the diastolic baseline, from the MAP upstroke to the desired repolarization level. The interval (ms) at 90% repolarization was defined as MAP 90 .
The heart was electrically driven using a cardiac stimulator (SEC-3102, Nihon Kohden) with the pacing electrodes of the combination catheter placed in the right ventricle. The stimulation pulses were rectangular in shape, 1 -2 V (about twice the threshold voltage) and of 1-ms duration. The MAP 90 was measured during sinus rhythm (MAP 90(sinus) ) and at a pacing cycle length of 400 ms (MAP 90(CL400) ) and 300 ms (MAP 90(CL300) ). The ERP of the right ventricle was assessed by the programmed electrical stimulation. The pacing protocol consisted of 8 beats of basal stimuli in a cycle length of 400 ms followed by an extra stimulus of various coupling intervals. Starting in late diastole, the coupling interval was shortened in 5 -10-ms decrements until refractoriness occurred. The duration of the terminal repolarization period (TRP) of the ventricle, namely, phase 3 repolarization of the action potential, was calculated by the difference between the MAP 90(CL400) and ERP at the same site, which reflects the extent of electrical vulnerability of the ventricular muscle (18) .
Experimental protocol
The systemic blood pressure, left ventricular pressure, ECG, His bundle electrogram, and MAP signals were monitored using a polygraph system (RM-6000, Nihon Kohden), and analyzed using a real time full automatic data analysis system (MP/ VAS 3 for Macintosh ver 1.0; Physio-Tech, Tokyo). Each measurement of ECG, MAP as well as atrio-His (AH) and His-ventricular (HV) intervals was the mean of three recordings of consecutive complexes. The cardiovascular variables were assessed in the following order. The CO was measured twice. The ECG, His bundle electrogram, systemic and left ventricular pressure, and MAP signal were recorded under sinus rhythm. In addition, MAP signals were recorded during the ventricular pacing at a cycle length of 400 and 300 ms. Then ERP was measured. All parameters described above were usually obtained within 1 min at each time point. After the basal assessment, potassium canrenoate in a low dose of 1 mg / kg was administered over 10 min and each parameter was assessed 5, 10, 15, 20, and 30 min after the start of the infusion. Then potassium canrenoate in a middle dose of 10 mg / kg, which is a clinically recommended daily maximum i.v. dose, was administered over 10 min, and each parameter was observed in the same manner. Finally, potassium canrenoate in a high dose of 100 mg / kg was administered over 10 min, and each parameter was observed 5, 10, 15, 20, 30, 45, and 60 min after the start of the infusion.
Plasma drug concentration
A volume of 3 ml of blood was drawn from the left femoral artery to measure the plasma drug concentration. The blood samples were centrifuged at 1,500´g for 30 min at 4°C. The plasma was stored at -80°C until the drug concentration was measured. Sensitive and specific determinations of the concentrations of potassium canrenoate were performed using a spectrofluorometric method of Gochman and Gantt (19) .
Drugs
Potassium canrenoate (monopotassium 17-hydroxy-3-oxo-17a -pregna-4,6-diene-21-carboxylate) (Soldactone Inj™; Pharmacia, Tokyo) was dissolved with saline in concentrations of 0.5, 5, and 50 mg / ml. Other drugs used were thiopental sodium (Tanabe, Osaka), halothane (Takeda, Tokyo), and heparin calcium (Nihon Schering, Osaka).
Statistical analyses
Data are presented as the mean ± S.E.M. Differences within a parameter were evaluated by one-way repeatedmeasures analysis of variance (ANOVA). When a P value was <0.05 by ANOVA, the drug was judged as having affected the parameter. In this case, statistical significance between the pre-drug control (C) and a value at a particular time point after the drug administration was determined by Contrasts for mean values comparison, and a P value <0.05 was considered significant.
Results
Two animals out of five died from cardiohemodynamic collapse during the experimental period, which occurred at 16 and 37 min after the start of the 100 mg / kg of potassium canrenoate infusion, respectively.
Effects on the heart rate and blood pressure
The time courses of changes in the heart rate and mean blood pressure are summarized in Fig. 1 (n = 5) and typical tracings of the blood pressure are depicted in Fig. 2 . The heart rate and mean blood pressure at the pre-drug control (C) were 124 ± 7 beats / min and 108 ± 5 mmHg, respectively. The heart rate and mean blood pressure decreased for 15 -60 and 5 -60 min after the start of the high dose of 100 mg / kg infusion, respectively.
Effects on the CO and TPR
The time courses of changes in the CO and TPR are summarized in Fig. 1 (n = 5) . The CO and TPR at the pre-drug control (C) were 1.41 ± 0.12 L / min and 79 ± 7 mmHg × min / L, respectively. The CO and TPR decreased for 10 -20 and 5 -60 min after the start of the high dose infusion, respectively.
Effects on the LVdP / dt max and LVEDP
The time courses of changes in the LVdP / dt max and LVEDP are summarized in Fig. 1 (n = 5) and typical tracings of the left ventricular pressure are depicted in Fig. 2 . The LVdP / dt max and LVEDP at the pre-drug control (C) were 1,849 ± 229 mmHg / s and 14.0 ± 2.7 mmHg, respectively. The LVdP / dt max decreased for 10 -30 min after the start of the high dose infusion, whereas no significant change was detected in the LVEDP during the experimental period.
Plasma drug concentration
The time course of the plasma drug concentration are summarized in Fig. 1 (n = 5) . The decrease of the plasma concentration followed a pattern predicted by the two-compartment theory of pharmacokinetics. The peak plasma concentrations of the drug after 1, 10, and 100 mg / kg infusion were 11 ± 2, 127 ± 13, and 2,360 ± 374 m g / ml, respectively.
Effects on the ECG
Typical tracings of the ECG are depicted in Fig. 2 , and the time courses of changes in the PR interval, QRS width, QT interval, and QTc are summarized in Fig. 3 (n = 5). The PR interval, QRS width, QT interval, and QTc corrected by Bazett's and Van de Water's formulas at the pre-drug control (C) were 107 ± 4, 67 ± 6, 268 ± 21, 383 ± 26, and 313 ± 20 ms, respectively. The QT interval and QTc corrected by Van de Water's formula were prolonged for 15 -60 min after the start of the high-dose infusion. The PR interval, QRS width, and QTc corrected by Bazett's formula tended to be prolonged, but did not achieve statistical significance.
Effects on the AH and HV intervals and MAP duration during the sinus rhythm
Typical tracings of the His bundle electrogram and MAP are depicted in Fig. 2 , and the time courses of changes in the AH and HV intervals and MAP 90(sinus) during the sinus rhythm are summarized in Fig. 3 (n = 5). The AH and HV intervals and MAP 90(sinus) at the pre-drug control (C) were 76 ± 4, 31 ± 2, and 243 ± 14 ms, respectively. The AH and HV intervals and MAP 90(sinus) were all prolonged. Significant changes were observed in the AH interval for 45 -60 min after the start of high-dose infusion, in the HV interval for 20 -30 min after the middle-dose infusion and for 10 -60 min after the high-dose infusion, and in the MAP 90(sinus) for 15 -60 min after the high-dose infusion.
Effects on the MAP 90 during the ventricular pacing
The time courses of changes in MAP 90 during the ventricular pacing at a cycle length of 400 and 300 ms are summarized in Fig. 3 (n = 5) . The MAP 90(CL400) and MAP 90(CL300) at the pre-drug control (C) were 245 ± 13 and 225 ± 10 ms, respectively. Both the MAP 90(CL400) and MAP 90(CL300) were prolonged. Significant changes were observed in the MAP 90(CL400) for 15 -60 min after the start of high-dose infusion and in the MAP 90(CL300) for 15 -20 min and at 45 min after the start of high-dose infusion. It should be noted that the time course of QTc corrected by Van de water well correlated with that of MAP 90(CL400) . The time courses of the increments in the MAP 90(CL400) and MAP 90(CL300) were also calculated (not shown in the figure) . Increment in the MAP 90(CL400) was greater than that in the MAP 90(CL300) at 15 min after the start of the high-dose infusion, indicating reverse usedependent prolongation of the repolarization period.
Effects on the ERP and TRP
The time courses of changes in the ERP and TRP are summarized in Fig. 3 (n = 5) . The ERP and TRP at the pre-drug control (C) were 225 ± 12 and 20 ± 4 ms. The ERP was prolonged for 5 -60 min after the start of the high-dose infusion, whereas the TRP was shortened for 5 -30 min after the high-dose infusion, resulting in the appearance of post-repolarization refractoriness.
Discussion
Given the lack of information regarding the proarrhythmic potential of spironolactone, in the present study we examined the cardiohemodynamic and electrophysiological effects of potassium canrenoate using the well-established halothane-anesthetized in vivo canine model (9 -15) . Potassium canrenoate is freely soluble in water and has been administered orally or intravenously (20) . Since clinically recommended intravenous doses of potassium canrenoate are 100 -200 mg / body in Japan (drug information from the manufacturer), the doses of the drug in this study can be considered to provide sub-therapeutic to supra-therapeutic levels of plasma drug concentrations. More importantly, potassium canrenoate produced rapid cardiovascular effects, supporting the previous concept that the acute effects of canrenoate may be independent of any modification of the electrolytes and / or water balance via its aldosterone receptor-blocking action (1 -3) .
Cardiohemodynamic effects
The low dose of 1 mg / kg as well as the middle dose of 10 mg / kg hardly affected any of the cardiohemodynamic parameters. On the other hand, the high dose of 100 mg / kg decreased the TPR and CO, which induced a severe hypotension in some animals. Previous studies have indicated that the hypotensive action could be induced through an inhibition of voltage-dependent Ca 2+ channels on the smooth muscle cells (21 -23) in addition to re-activation of the Na + / K + ATPase inhibited by high levels of endogenous ouabain-like factor (24, 25) . While the hypotensive effect should increase the reflex-mediated adrenergic tone, the sinus automaticity and ventricular contraction were both suppressed in this study, suggesting that higher dose of potassium canrenoate may also exert direct negative chronotropic and inotropic effects on the heart. These cardiohemodynamic effects were essentially in accordance with the previous in vitro and in vivo observations (3, 4, 25) . Also, it should be noted that the extent of changes in these variables largely paralleled the time course of the plasma drug concentration.
Electrophysiological effects
Although the increased sympathetic tone may have enhanced the atrioventricular nodal conduction, AH interval was slightly prolonged after the blood pressure started to return to the basal level, supporting the previous report that potassium canrenoate could block Ca 2+ channels of the heart (25) . Meanwhile, intraventricular conduction delay together with the prolongation of ERP indicates that potassium canrenoate can also inhibit ventricular Na + channels, which is in good accordance with the previous in vitro observations (2, 3) . The low and middle doses of potassium canrenoate did not affect the repolarization speed. Since spironolactone can be metabolized very rapidly to canrenoate (19, 20) , therapeutic doses of spironolactone as well as potassium canrenoate can be considered to be administered without risk of lethal arrhythmias related to the excessive QT interval prolongation. Moreover, the highest dose of potassium canrenoate prolonged the MAP duration in a reverse frequency-dependent manner, in which the prolonging effect on the repolarization phase was more prominent at slower heart rate. This phenomenon is quite similar to that observed by selective I Kr -channel blockers, including dofetilide and cisapride, in the same animal model as used in this study (11, 12) , suggesting that the mixed I Kr -and I Ks -blocker potassium canrenoate could also exert its I Kr -blocking properties in the in situ beating heart. This hypothesis is further supported by previous in vitro data that the IC 50 value of canrenoate for HERG current was 104.3 mM (= 41.4 m g / ml) (5) . Since approximately 98% of the drug is bound to plasma protein (20) , plasma drug concentration for inhibiting the cardiac K + channels can be estimated to be around 2 mg/ ml, which was attained after the high-dose infusion in this study.
Antiarrhythmic/proarrhythmic potential
It is well known that impulses that reach the ventricles during the middle and terminal portions of the T wave can initiate the ventricular tachycardias and fibrillation, since the repolarization is most heterogeneous and sodium channels are in different phases of recovery during this period (18) . In the halothane-anesthetized animal model, such an electrically vulnerable period can be estimated by TRP (9 -15) and drug-induced prolongation of TRP has been known to increase the potential for slow conduction and reentry that allows perpetuation of torsades de pointes (9, 14, 18, 26, 27) . Moreover, prolongation of this phase could generate early afterdepolarizations by spending too much time in the window voltage for Ca 2+ channel reactivation (28) . In this study, we found that the high dose of potassium canrenoate shortened the TRP, supporting its previously reported antiarrhythmic potential (2, 3, 4) . It should be noted that similar electrophysiological profile have been confirmed for amiodarone i.v. in our previous study using the same canine experimental model system (13) .
Study limitations
Hypotension observed after the high dose administration may have modified the electrophysiological properties of the in situ heart, which usually shortens the QT interval via the increased sympathetic tone in vivo (29) . Also, long-term electrophysiological effects of canrenoate needs to be assessed, since extracellular potassium concentration would increase after the chronic administration of canrenoate, which might blunt the blockade of HERG channels, resulting in the suppression of the development of excessive QTinterval prolongation (30) .
Conclusions
Currently observed unique electrophysiological profile of potassium canrenoate may at least in part contribute to the clinically demonstrated therapeutic efficacy of the parent compound spironolactone in the treatment of chronic heart failure. However, caution must be paid to its cardiohemodynamic actions, particularly for patients with risk of elevated plasma drug concentration.
